Literature DB >> 9292630

Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity.

P Sargent1, D J Williamson, G Pearson, J Odontiadis, P J Cowen.   

Abstract

Animal experimental studies suggest that the therapeutic effect of selective serotonin re-uptake inhibitors (SSRIs) may involve neuroadaptive changes in pre- and post-synaptic serotonin1A (5-HT1A) receptors. We used the endocrine and hypothermic responses to the 5-HT1A receptor agonist, gepirone (20 mg orally), to assess 5-HT1A receptor sensitivity in 37 healthy male volunteers who were studied before and following random double-blind, allocation to treatment with paroxetine, nefazodone or placebo for 17 days. Following antidepressant drug treatment, hypothermic responses to gepirone were markedly decreased by paroxetine but only slightly diminished by nefazodone. Paroxetine also lowered the growth hormone and cortisol responses to gepirone. There was no change in either hypothermic or endocrine response following placebo treatment. Our results suggest that paroxetine treatment produces a striking attenuation of measures of both pre- and post-synaptic 5-HT1A receptor function. Nefazodone appears to decrease the sensitivity of 5-HT1A autoreceptors to some extent and this effect may contribute to its antidepressant activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292630     DOI: 10.1007/s002130050348

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

1.  GPR30 is necessary for estradiol-induced desensitization of 5-HT1A receptor signaling in the paraventricular nucleus of the rat hypothalamus.

Authors:  C E McAllister; R D Creech; P A Kimball; N A Muma; Q Li
Journal:  Psychoneuroendocrinology       Date:  2012-01-20       Impact factor: 4.905

2.  GPER1 stimulation alters posttranslational modification of RGSz1 and induces desensitization of 5-HT1A receptor signaling in the rat hypothalamus.

Authors:  Carrie E McAllister; Zhen Mi; Minae Mure; Qian Li; Nancy A Muma
Journal:  Neuroendocrinology       Date:  2014-11-07       Impact factor: 4.914

3.  Pharmacology of ayahuasca administered in two repeated doses.

Authors:  Rafael G Dos Santos; Eva Grasa; Marta Valle; Maria Rosa Ballester; José Carlos Bouso; Josep F Nomdedéu; Rosa Homs; Manel J Barbanoj; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2011-08-13       Impact factor: 4.530

4.  Contrasting effects of citalopram and reboxetine on waking salivary cortisol.

Authors:  C J Harmer; Z Bhagwagar; N Shelley; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  2003-02-26       Impact factor: 4.530

Review 5.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

6.  Elevated prolactin responses to L-tryptophan infusion in medication-free depressed patients.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Margaret S Smith; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2003-05-01       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.